Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25435787 | 0.87 | TSHR (0.54) | TSHRTDP1MEN1KMT2ALMNA | |
| SCHEMBL37351 | 0.87 | TSHR (0.54) | TSHRTDP1MEN1KMT2ALMNA | |
| Ammonia Solution, Strong SCHEMBL9998248 | 0.85 | TSHR (0.52) | TSHRTDP1MEN1KMT2ALMNA | |
| SCHEMBL16904025 | 0.82 | ALDH1A1 (0.33) | TDP1MEN1KMT2ALMNACYP3A4 | |
| Ethylene Glycol SCHEMBL14991179 | 0.80 | TSHR (0.48) | TSHRTDP1MEN1KMT2ALMNA | |
| SCHEMBL13133074 | 0.80 | TSHR (0.48) | TSHRTDP1MEN1KMT2ALMNA | |
| SCHEMBL575095 | 0.79 | — | — | |
| SCHEMBL28468134 | 0.79 | SMN1; SMN2 (0.34) | MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL22517943 | 0.78 | PTGS2 (0.42) | PTGS1 | |
| SCHEMBL17194018 | 0.78 | TSHR (0.52) | TSHRTDP1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| CN-110183490-A | A kind of Preparation method and use of Tenofovir | 北京鑫开元医药科技有限公司 | 2019-08-30 | — | — | CN | claimed |
| US-9907796-B2 | Methods of treating tumoral diseases, or bacterial or viral infections | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | SPHAERA PHARMA PTE. LTD. (SG) | 2017-01-05 | — | — | US | claimed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922695-A | COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS | GILEAD SCIENCES, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | TSHR 3151/4885TDP1 2511/4885MEN1 260/4885 |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | POLI, RNASE1, VHL | TSHR 4292/4885TDP1 2637/4885MEN1 180/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | TSHR 399/4885TDP1 305/4885MEN1 949/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | TSHR 2320/4885TDP1 1289/4885MEN1 4627/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | TSHR 4553/4885TDP1 2699/4885MEN1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.